Table 1.

Overview of the ‘Chinese‐Way’ Therapeutic Agents for COVID‐19 (Modified from [17‐23]).

Agent	Indication	Direction	ClinicalTrials.gov Identifier Number* (Current Recruitment Status)
IFN‐alpha	Broad‐spectrum antivirus	5 million U bid inh	ClinicalTrials.gov identifier number not available
Lopinavir/ritonavir	Anticoronavirus	400 mg/100 mg bid po	NCT04255017 (R)
Ribavirin	Nucleoside analogs	500 mg bid/tid iv	ClinicalTrials.gov identifier number not available
Chloroquine phosphate	Antimalaria; 18 ≤ age ≤ 65	W ≥ 50 kg: d1‐d7 500 mg bid; W < 50 kg: d1‐d2: 500 mg bid, d3‐d7: 500 mg qd. time ≤ 7d	ClinicalTrials.gov identifier number not available
Arbidol	Anticoronavirus	200 mg tid po	ClinicalTrials.gov identifier number not available
Tocilizumab	Antagonist of IL‐6R	4–8 mg/kg	NCT04306705 (R), NCT04310228 (R)
Remdesivir	Anticoronavirus	—	NCT04252664 (S), NCT04257656 (T), NCT04292899 (R)
TCM	—	syndrome differentiation	NCT04306497 (R), NCT04251871 (R), NCT04323332 (NR)

NR, not yet recruiting; bid, bis in die; inh, inhalation; iv, intravenous; po, per os; qd, quaque die; R, recruiting; S, suspended; T, terminated; TCM, traditional Chinese medicine; tid, ter in die; W, weight.

^*Only numbers from clinical trials which conducted in China till 5 May 2020. URL: https://clinicaltrials.gov/ct2/results?cond=COVID‐19.